CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment…
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development for the treatment of obesity…
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA")…
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult…
Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology HoldingsBiotechnology Veteran Bas van…
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE,…
In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ETSAN DIEGO,…
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms…